Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020

Rhea-AI Summary

Agile Therapeutics (Nasdaq: AGRX) announces it will release its third quarter 2020 financial results on November 12, 2020, after market close. A live conference call and webcast will follow at 4:30 p.m. ET for discussing the results and providing a business update. Investors can join the conference call by calling (877) 407-2991 for U.S. callers or (201) 389-0925 internationally. The company focuses on women's healthcare, particularly offering contraceptive options through its product Twirla®, utilizing its Skinfusion® transdermal technology.

Positive

• Scheduled financial results release indicates transparency and engagement with investors.

Negative

• None.

Live Conference Call and Webcast at 4:30 p.m. ET

PRINCETON, N.J., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2020 financial results after the market close on Thursday, November 12, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.

Investors interested in listening to the conference call may do so by dialing (877) 407-2991 for domestic callers or (201) 389-0925 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.

Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.

Follow Agile on LinkedIn and Twitter: @AgileTher.

Source: Agile Therapeutics

Contact: 
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com

FAQ

When will Agile Therapeutics report its third quarter 2020 financial results?

Agile Therapeutics will report its third quarter 2020 financial results on November 12, 2020, after market close.

What is the purpose of the conference call on November 12, 2020, by Agile Therapeutics?

The conference call aims to discuss the third quarter financial results and provide a business update.

How can investors access the Agile Therapeutics conference call?

Investors can access the call by dialing (877) 407-2991 for domestic calls or (201) 389-0925 for international calls.

What product does Agile Therapeutics offer?

Agile Therapeutics offers Twirla®, a transdermal contraceptive patch designed to provide an alternative to daily pills.